Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults
04:01pm, Tuesday, 04'th Mar 2025
RHHBY's member company, Genentech, obtains FDA nod for TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
David Roche: ‘NATO is dead' and Europe defense spending needs to increase
12:15am, Tuesday, 04'th Mar 2025
Quantum Strategy's David Roche says Europe's defense spending needs to increase by at least $200 billion as he discusses the clash between U.S. President Donald Trump and Ukrainian President Volodymyr
FDA Approves Genentech's TNKase® in Acute Ischemic Stroke in Adults
11:45am, Monday, 03'rd Mar 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase�
F. Hoffmann-La Roche Digital Transformation Analysis Report 2024: Accelerators, Incubators, and Innovation Programs
06:03am, Monday, 03'rd Mar 2025
Dublin, March 03, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: F. Hoffmann - La Roche Ltd 2024" report has been added to ResearchAndMarkets.com's offering.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new positive data from Stage 2 and Stage 3 of the National Institutes
Basel, 2 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which
CHMP recommends EU approval of Roche's Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
08:15am, Friday, 28'th Feb 2025
Basel, 28 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of
David Roche: Germany's coalition government, a 'bumpy ride' going in the right direction
06:30am, Friday, 28'th Feb 2025
David Roche of Quantum Strategy discusses his optimism for the new German government following their recent elections. He believes the new government will be able enact reforms both domestically and o
Roche: Sustainable Sales Growth, Margin Leverage, And Supportive Late-Stage Pipeline
08:53pm, Wednesday, 26'th Feb 2025
Q4 results reinforce our positive outlook on Roche, highlighting the company's resilience and strategic advancements. Solid performance of Ocrevus and Vabysmo are key drivers of near-term top-line sal
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
01:30pm, Thursday, 20'th Feb 2025
Basel, 20 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) unveiled today its proprietary, breakthrough sequencing by expansion (SBX) technology, establishing a new category of next-generation seque
Yemaachi Biotechnology Launches The African Cancer Atlas, in Partnership with Roche
02:03pm, Tuesday, 18'th Feb 2025
ACCRA, Ghana & WASHINGTON--(BUSINESS WIRE)-- #cancerresearch--Yemaachi Biotech, a pioneering genomics research company based in Ghana, announced today a partnership with Roche to launch The African Ca
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
10:05am, Thursday, 13'th Feb 2025
DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching U
FDA Approves Genentech's Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
11:45am, Wednesday, 12'th Feb 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New D
FDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
11:45am, Wednesday, 12'th Feb 2025
Basel, 12 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam) ta
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of its Phase III REGENCY trial of Gazyva® (
